Dyne Therapeutics, Inc. (DYN) Stock Profile — Insider Trades & Financials

Net Income-$112.0M

EPS$-0.73

Market Cap$3.0B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

John Cox

CEO & Executive Director

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Founded: 1984
Employees: 258
Headquarters: Waltham, Massachusetts, United States

⚡

Core Efficiency

ROE?

-11.52%

ROA?

-9.43%

D/E Ratio?

0.22

📊

Profitability Ratios

Current Ratio?

22.25

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jun 2, 2026 (in 54 days)

Annual Report (10-K) — Based on filing pattern

Jun 2, 2026

Predicted10-K

Mar 2, 2026

10-KQ4 202561d after period end

Mar 2, 2026

10-KFY 202561d after period end

Nov 5, 2025

10-QQ3 20255d after period end

Jul 28, 2025

10-QQ2 20253d after period end

May 8, 2025

10-QQ1 202513d after period end

Feb 27, 2025

10-KQ4 20246d after period end

Feb 27, 2025

10-KFY 202558d after period end

Nov 12, 2024

10-QQ3 20244d after period end

Loading company sections...

Dyne Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness